Enterome to present positive interim Phase 2 data for lead OncoMimics™ immunotherapy EO2463 in follicular lymphoma at American Society for Hematology (ASH) meeting
Read more
16
October 2025
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
Read more
23
June 2025
The widely read BioWorld biopharmaceutical daily took a comprehensive look at Enterome’s work after the success of our $19 million funding round to advance the EO2463 non-Hodgkin lymphoma therapy.
Read more
23
June 2025
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
Read more
12
June 2025
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
Read more
02
June 2025
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
